Anzupgo (delgocitinib): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

If your hands have been living a double lifetrying to look normal in public while privately cracking, burning, and peeling like they’re auditioning for a “before” photochronic hand eczema (CHE) may be the culprit. CHE isn’t just “dry hands.” It can be a stubborn, work-ruining, sleep-stealing skin condition that often needs more than “apply lotion and pray.”

Anzupgo (delgocitinib) is a prescription, steroid-free cream made specifically for moderate to severe chronic hand eczema in adults when topical steroids haven’t helped enough (or aren’t a great idea for you). Below is an in-depth, plain-English guide to what it’s for, how it works, how to use it, what to watch for, and what to do if your hands decide to be dramatic anyway.

Quick facts (for busy hands)

• What it is: A topical (skin-applied) Janus kinase (JAK) inhibitor cream containing delgocitinib 2%.
• What it treats: Moderate to severe chronic hand eczema (CHE) in adults when topical corticosteroids are inadequate or not advisable.
• How you use it: Apply a thin layer twice daily to affected areas only on the hands and wrists.
• Don’t overdo it: Do not use more than 30 grams per 2 weeks or 60 grams per month.
• Big-picture warnings: Infection risk, possible viral reactivation (like shingles), non-melanoma skin cancer monitoring, and vaccine guidance.
• Interaction headline: Don’t combine with other JAK inhibitors or potent immunosuppressants unless your prescriber specifically directs it.

What is Anzupgo (delgocitinib)?

Anzupgo is a prescription cream for topical use that contains delgocitinib, a medicine in the Janus kinase (JAK) inhibitor class. Unlike oral (pill) JAK inhibitors used for certain inflammatory diseases, Anzupgo is designed to be applied to the skinspecifically the hands and wriststo help calm inflammation linked with chronic hand eczema.

It’s also worth saying out loud: Anzupgo is not a steroid. Many people with CHE have already done the steroid shufflestronger steroid, short break, flare again, repeatand are looking for an effective steroid-free option tailored to hands.

What is chronic hand eczema (CHE), and why is it such a pain (literally)?

Chronic hand eczema is hand dermatitis that sticks around for a long timeoften defined as lasting more than a few months or coming back repeatedly. It commonly shows up as dry, thickened, cracked, red, scaly, itchy, painful skin on the hands, fingers, and wrists. Some people also get blistering (often described with dyshidrotic eczema), while others have rough, thick plaques (hyperkeratotic hand eczema).

Hands are a perfect storm for eczema because they’re exposed to… well, everything. Water, soap, sanitizer, cleaning products, gloves, metals, fragrances, workplace chemicals, cold air, heat, and stressyour hands basically work customer service without breaks. CHE is also commonly linked to irritant contact dermatitis and allergic contact dermatitis, and it can overlap with atopic dermatitis.

Common triggers and “repeat offenders”

• Irritants: frequent handwashing, detergents, solvents, disinfectants, wet work, friction.
• Allergens: fragrances, preservatives, rubber/latex additives, metals like nickel, and other contact allergens (patch testing can help identify these).
• Environment: cold/dry weather, sweating/moisture under gloves, humidity changes.
• Stress and sleep disruption: because eczema loves a messy schedule.

Uses: what Anzupgo is approved to treat

Anzupgo is indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to topical corticosteroids, or for whom topical corticosteroids are not advisable.

Limitations of use

Using Anzupgo in combination with other JAK inhibitors or potent immunosuppressants is not recommended. It’s also not indicated for rheumatoid arthritis (RA), and it’s not known whether it is safe and effective in children.

How Anzupgo works (JAK inhibitors, explained without a biology headache)

Delgocitinib inhibits the activity of JAK1, JAK2, JAK3, and TYK2. These enzymes are part of signaling pathways used by multiple cytokines (immune “messenger” proteins). When those signals run hot, inflammation increasesfueling redness, itching, swelling, and barrier damage in eczema.

By reducing JAK-driven signaling, topical delgocitinib helps dial down inflammatory activity in the skin. The label notes that the exact mechanism for treating moderate to severe CHE is not fully knownwelcome to modern medicine, where we often know what works before we can explain every microscopic detail of why.

Dosing & how to apply (step-by-step)

Standard dosing

• Clean and dry the affected areas before applying.
• Apply a thin layer twice daily to the affected areas only on the hands and wrists.
• Do not use more than 30 grams per 2 weeks or 60 grams per month.
• Anzupgo is for topical use only: not for oral, ophthalmic (eyes), or intravaginal use.
• Avoid contact with eyes, mouth, or other mucous membranes; rinse thoroughly with water if contact occurs.

Practical application tips (the “my hands are busy” edition)

• Use a “thin layer” mindset: this isn’t frostingyour hands don’t need to look glazed.
• Pick a routine anchor: after brushing teeth, after dinner cleanup, or right before bedsomething you already do.
• If your hands are fissured (cracked): you may feel stinging with many topical products. If it’s intense or persistent, let your prescriber know.
• Don’t apply on visibly infected skin (oozing, honey-colored crusting, rapidly worsening warmth/swelling) without medical guidancecall your clinician.

If you miss a dose

Apply it when you remember, then continue your normal schedule. If it’s almost time for the next dose, skip the missed dosedon’t double up. (Your hands are already doing too much; don’t make them do math, too.)

What results to expect (and what “success” looked like in trials)

The main clinical studies evaluated Anzupgo in adults with moderate to severe CHE over 16 weeks, with people applying the cream twice daily to the hands and wrists. Researchers used an investigator rating scale for chronic hand eczema severity (IGA-CHE) and patient-reported symptom diaries for itch and pain.

Skin clearance and symptom improvement

At Week 16, a greater proportion of people using Anzupgo achieved “treatment success” (clear or almost clear with meaningful improvement) compared with vehicle cream. Improvements were also seen in patient-reported itch and pain scores, with higher response rates versus vehicle.

Longer-term safety snapshot

Some participants continued into a longer-term extension study. Long-term studies help clinicians understand what happens beyond the initial “first 16 weeks” windowimportant for a condition that likes to relapse the moment you let your guard down.

Side effects: what you may notice

In trials, adverse reactions reported in a small percentage of people included local application site effects and some infections or lab changes. Your personal risk depends on your overall health, skin barrier status, and whether you’re prone to infections.

Possible side effects (reported in clinical studies)

• Application site effects: pain, paresthesia (stinging/burning sensation), itching, redness.
• Skin infections: bacterial skin infections (including finger cellulitis, paronychia, and other skin infections).
• Blood count changes: leukopenia and neutropenia were reported (rare).

Less common but important events noted in longer-term use

• Eczema herpeticum (painful, blistering rash caused by herpes virus infection in eczema-affected skin).
• Herpes zoster (shingles).

If you develop signs of infection (fever, chills, worsening skin pain, spreading redness, blisters, or feeling unusually unwell), contact your healthcare provider promptly.

Warnings & precautions (the “read this even if you never read manuals” section)

1) Serious infections

Anzupgo may increase the risk of infections. Serious infections have been reported with oral or topical JAK inhibitors, and the medication guide emphasizes that JAK inhibitors can lower the immune system’s ability to fight infections. You should not start Anzupgo if you have an active serious infection unless your healthcare provider tells you it’s okay.

2) Viral reactivation (including shingles)

Viral reactivation (including herpes zoster) was reported in clinical trials. If shingles develops, your clinician may consider interrupting treatment until the episode resolves. The impact on chronic viral hepatitis reactivation is unknown; patients with active hepatitis B or C were excluded from trials, and Anzupgo is not recommended for use in people with active hepatitis B or hepatitis C.

3) Non-melanoma skin cancers

Non-melanoma skin cancers (including basal cell carcinoma) have been reported in subjects treated with Anzupgo. Periodic skin examinations of the application sites are recommendedespecially if you have additional risk factors for skin cancer. Avoid sunlamps and minimize sun exposure with protective clothing and broad-spectrum sunscreen.

4) Vaccines and immunizations

Before starting Anzupgo, complete recommended immunizations, including herpes zoster (shingles) vaccination when appropriate. Avoid live vaccines immediately prior to, during, and immediately after treatment. If you’re unsure whether a vaccine is “live,” askbecause guessing is not a medical strategy.

5) “Class warnings” for JAK inhibition: what this means for a topical cream

Large safety studies of an oral JAK inhibitor in rheumatoid arthritis (RA) populations have shown higher rates of serious outcomes (including major cardiovascular events, thrombosis, certain cancers, and all-cause mortality) compared with TNF blockers in higher-risk patients. Anzupgo is not approved for RA, and the label notes it is not known whether Anzupgo is associated with these observed or potential adverse reactions of JAK inhibition.

Translation: topical exposure is generally much lower than with pills, but prescribers still consider your overall risk profile (age, smoking history, cardiovascular risk, infection history, cancer history) when deciding what’s right for you.

Interactions: medications, vaccines, and “product layering” on hands

Drug-drug interactions

Drug interaction studies with Anzupgo have not been conducted. In vitro data suggest delgocitinib does not inhibit or induce major cytochrome P450 enzymes or key transporter systems at clinically relevant concentrations. Still, clinical caution is advised because real life is messier than lab dishes.

What you should tell your clinician about

• Other JAK inhibitors: oral or topical (combination is not recommended).
• Potent immunosuppressants: because of additive immune effects.
• Recent vaccines or planned vaccines: especially live vaccines.
• History of shingles, eczema herpeticum, or recurrent infections.

Topical “interactions” (hand creams, sanitizers, gloves)

The prescribing information focuses on applying Anzupgo to clean, dry skin and avoiding mucous membranes. If you use multiple products on your hands (moisturizers, barrier creams, sanitizers, occupational creams), ask your clinician or pharmacist how to time them. A simple rule that often helps: apply prescription medication as directed, let it absorb, then use supportive moisturizers as part of your hand care planwithout turning your hands into a 12-step skincare routine you’ll abandon by Tuesday.

Pharmacology “in human words”: absorption and why topical matters

In pharmacokinetic testing, systemic (blood) levels after topical application were low, and there was no evidence of drug accumulation with twice-daily use over the short PK study window. This low systemic exposure is one reason topical therapies can offer a favorable balance for skin-limited diseasethough “low” does not mean “zero,” and warnings still matter.

Pregnancy, breastfeeding, and special populations

Pregnancy

Human data on topical delgocitinib use in pregnancy are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or other outcomes. If you are pregnant or planning pregnancy, discuss the risks and benefits with your healthcare provider.

Breastfeeding

It’s not known whether Anzupgo passes into breast milk. The patient counseling guidance advises breastfeeding women to avoid direct contact of the infant with the nipple and surrounding area immediately after applying Anzupgo to the hands and/or wrists to minimize infant exposure.

Pediatrics and older adults

It is not known if Anzupgo is safe and effective in children. In older adults studied in trials, no overall differences in safety or effectiveness were observed compared with younger adults, but individual risk factors still matter.

“Pictures”: what Anzupgo looks like (and how to verify the right product)

Since this page can’t hand you an actual photo (pun fully intended), here’s how the product is described in official labeling and what to check when you’re holding the tube.

Appearance and packaging cues

• Form: Cream, 2% (each gram contains 20 mg delgocitinib).
• Color/texture description: White to slightly brown cream (color can vary slightly).
• Tube sizes: 30 g and 60 g laminated tubes.
• Storage: Store at controlled room temperature (generally 20°C to 25°C / 68°F to 77°F); do not freeze.

How to “ID” your tube like a cautious adult

• Check the drug name (Anzupgo) and generic (delgocitinib).
• Confirm the strength (2% cream).
• Match the tube/carton to what your pharmacy label says.
• Check the expiration date and keep it stored properly.

FAQ (because your hands already asked me these)

Is Anzupgo a steroid?

No. It’s a steroid-free topical JAK inhibitor.

Can I use it on eczema elsewhere on my body?

It’s indicated for use on the affected areas only on the hands and wrists. If you have eczema elsewhere, ask your clinician about options for those areas.

Do I need lab monitoring?

Many people won’t need routine lab monitoring solely for a topical medication, but rare blood count changes were reported. Your clinician will decide based on your health history, other medications, and risk factors.

Will it cure my chronic hand eczema forever?

CHE is often a long-term condition with flares driven by triggers (irritants/allergens). Medications help control inflammation, but long-term control usually also involves trigger management, barrier support, and sometimes patch testing or occupational adjustments.

Real-world experiences and practical tips

Clinical trials tell us what happens on average. Real life tells us what happens at 7:42 a.m. when you’re late, your hands are burning, and you still have to open a childproof cap designed by someone who clearly had perfect skin. Here are common “experience-based” themes that patients and clinicians often talk about when managing chronic hand eczema and introducing a prescription topical like Anzupgo. Think of this as the street-smarts companion to the prescribing instructions.

1) The emotional whiplash is real

People with CHE often describe a weird mix of embarrassment and exhaustion: you don’t want to shake hands, your fingers split when you fold laundry, and you start avoiding hobbies that involve water, dust, or friction. When treatment finally reduces itch and pain, it’s not “just cosmetic”it can feel like getting your life back. Many patients say the biggest relief isn’t only the skin looking calmer; it’s the ability to do normal tasks without bracing for pain.

2) Early sensations: stinging doesn’t always mean “bad,” but it shouldn’t be ignored

On cracked, inflamed hands, almost anything can stingincluding plain water, so it’s not shocking that a topical medication might cause temporary stinging or burning sensations for some people. The key is pattern recognition:

• Short-lived, mild stinging right after applying can happen with irritated skin.
• Persistent burning, worsening redness, swelling, or rash spread may signal irritation, allergy, or infection and deserves a call to your prescriber.

People often find that as the skin barrier improves, those early sensations can lessenone more reason consistent hand care matters.

3) The “supporting cast” matters: moisturizers, gloves, and timing

In the real world, very few hands live in a vacuum. They wash dishes, sanitize, wear gloves, touch paper, and get blasted by winter air-conditioning like it’s personal. Many clinicians encourage a two-part plan: anti-inflammatory treatment (like your prescription) plus barrier repair (thick, bland moisturizers and trigger avoidance).

A practical routine people stick with often looks like this:

• Gentle cleanser (or lukewarm water rinse when possible) instead of harsh soaps.
• Moisturize after washingespecially with thicker creams/ointments if tolerated.
• Use protective gloves strategically: cotton liners under nitrile gloves for wet work, and avoid prolonged sweaty occlusion when possible.
• Pick a “minimum effective routine” you can actually maintain, not a 14-step plan that collapses the first time you travel.

4) Trigger detective work pays off (especially for hands)

A huge number of “treatment failures” are really “trigger wins.” For example:

• A healthcare worker improves only after switching to gentler hand hygiene products and using barrier cream before shifts.
• A hairstylist flares until they identify a specific glove additive or hair product allergen.
• A home DIY fan keeps relapsing until they stop raw-dogging cleaning solutions and start wearing appropriate gloves (your hands are not indestructible, no matter how brave you feel holding a paint scraper).

If allergic contact dermatitis is suspected, clinicians may recommend patch testingbecause avoiding an allergen you don’t know you have is like trying to dodge a mosquito you can’t see.

5) People often track two things: function and flares

In conversations about CHE, many patients say the most meaningful outcomes are: less itch, less pain, fewer cracks, and better function (typing, cooking, childcare, work tasks). A simple weekly note“How bad was itch 0–10?” and “How many days did cracks bleed?”can help you and your clinician judge whether the plan is truly working or just “kind of, sometimes.”

6) Safety awareness becomes empowering, not scary

The infection and skin-cancer precautions can sound intimidating. Many people do best when they treat them like a checklist, not a panic button: stay current on recommended vaccines, watch for unusual infections, protect skin from excessive UV exposure, and keep regular follow-ups. If something feels offnew blisters, rapidly worsening pain, fever, or spreading rednesscalling early is usually the right move.

Bottom line: people tend to get the best results when medication is paired with realistic routines, trigger management, and a plan for flares. Your hands do a lot for you. It’s okay to return the favor.

Conclusion

Anzupgo (delgocitinib) is a prescription, steroid-free topical JAK inhibitor cream approved for adults with moderate to severe chronic hand eczema when topical steroids aren’t enough or aren’t advisable. Used correctlythin layer, twice daily, hands and wrists only, within the monthly gram limitsit can improve signs and symptoms like itch and pain for many patients.

CHE is often multifactorial, so the strongest game plan usually combines the right medication with barrier repair, trigger avoidance, and (when needed) evaluation for allergic contact dermatitis. If you’re starting Anzupgo, take the warnings seriouslybut not fearfully: know what to watch for, keep up with appropriate vaccines, and stay in touch with your clinician if anything changes.